Is Galectin Therapeutics, Inc. (GALT)’s Fuel Running Low? The Stock Reaches 52-Week High Today

June 18, 2018 - By Kurt Siggers

Galectin Therapeutics, Inc. (NASDAQ:GALT) Logo

Investors sentiment increased to 1.86 in Q1 2018. Its up 1.33, from 0.53 in 2017Q4. It is positive, as 7 investors sold Galectin Therapeutics, Inc. shares while 7 reduced holdings. 17 funds opened positions while 9 raised stakes. 4.02 million shares or 30.74% more from 3.08 million shares in 2017Q4 were reported.
Da Davidson And accumulated 0.07% or 731,300 shares. Jefferies Gru Limited Liability Corp has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Bank Of America Corp De has 8,260 shares for 0% of their portfolio. Art Advsr Limited Co holds 0.01% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 57,775 shares. Sei Invests has 3,800 shares. Schwab Charles Inv Management reported 21,400 shares stake. Neuberger Berman Grp Inc Ltd Liability reported 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Moreover, Bluecrest Cap Mgmt Limited has 0.01% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT). Northern Trust Corp stated it has 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Norris Perne French Llp Mi has invested 0.01% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Vanguard Gru holds 0% or 1.17 million shares in its portfolio. Courage Mngmt Ltd owns 0.11% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 30,000 shares. Dynamic Advisor Solutions Lc holds 10,000 shares or 0.01% of its portfolio. Barclays Public Limited Com owns 20,123 shares. Buckingham Asset Management Ltd Company holds 0.01% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 10,000 shares.

Since January 25, 2018, it had 2 insider buys, and 21 insider sales for $12.51 million activity. CALLICUTT JACK W had sold 46,651 shares worth $233,255. 10X Fund – L.P. sold 244,444 shares worth $1.33 million. $1.33M worth of stock was sold by CZIRR JAMES C on Thursday, January 25. 2,000 shares were bought by FREEMAN KEVIN D, worth $8,191 on Thursday, February 1. The insider ZUCCONI THEODORE DANIEL sold 4,000 shares worth $14,320. TRABER PETER G sold $409,997 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) on Friday, June 8.

The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) hit a new 52-week high and has $9.58 target or 4.00 % above today’s $9.21 share price. The 6 months bullish chart indicates low risk for the $347.59 million company. The 1-year high was reported on Jun, 18 by Barchart.com. If the $9.58 price target is reached, the company will be worth $13.90M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 5.26% or $0.46 during the last trading session, reaching $9.21. About 2.70 million shares traded or 286.00% up from the average. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 77.97% since June 18, 2017 and is uptrending. It has outperformed by 65.40% the S&P500.

Analysts await Galectin Therapeutics, Inc. (NASDAQ:GALT) to report earnings on August, 13. They expect $-0.14 EPS, 0.00 % or $0.00 from last year’s $-0.14 per share. After $-0.12 actual EPS reported by Galectin Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 16.67 % negative EPS growth.

More notable recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: Nasdaq.com which released: “Mid-Day Market Update: Pivotal Software Gains Following Q1 Results; Flex Pharma Shares Slide” on June 13, 2018, also Fool.com with their article: “3 NASH Stocks That Could Soar in the Second Half of 2018” published on June 15, 2018, Fool.com published: “3 Biotech Stocks That Soared This Week: Are They Buys?” on June 16, 2018. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) were released by: Globenewswire.com and their article: “Galectin Therapeutics Inc. Announces New CEO” published on June 12, 2018 as well as Nasdaq.com‘s news article titled: “2 Clinical-Stage Biotech Stocks That Could Soar Next Week” with publication date: June 17, 2018.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $347.59 million. The companyÂ’s lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.